The Experts below are selected from a list of 3861 Experts worldwide ranked by ideXlab platform

Charles L. Loprinzi - One of the best experts on this subject based on the ideXlab platform.

  • The Physical Consequences of Chemotherapy-Induced Peripheral Neuropathy.
    Current oncology reports, 2020
    Co-Authors: Cindy Tofthagen, Andrea L. Cheville, Charles L. Loprinzi
    Abstract:

    Chemotherapy-Induced Peripheral Neuropathy (CIPN) is a common side effect of numerous chemotherapy drugs. CIPN negatively impacts function and quality of life during and after treatment. We will provide a review of the data describing the physical consequences of CIPN and discuss the possible long term impact on emotional well-being and quality of life. CIPN negatively affects physical function and many aspects of quality of life. Exercise interventions are likely to reduce the risk of falls associated with CIPN. There remains a need for evidence-based interventions focused on improving symptoms, function, and quality of life in persons with CIPN.

  • Symptoms: Chemotherapy-Induced Peripheral Neuropathy.
    Advances in experimental medicine and biology, 2015
    Co-Authors: Bryan P. Schneider, Dawn L. Hershman, Charles L. Loprinzi
    Abstract:

    Chemotherapy-Induced Peripheral Neuropathy (CIPN) is a problematic, treatment-induced toxicity that has the potential to impact quality of life and limit the doses of curative intent therapy. This therapy-induced side effect is one of the most troublesome in oncology clinical practices, considering the morbidity, the frequency, and the potential irreversibility of this problem. Patients with breast cancer are particularly impacted by this side effect as multiple agents commonly used for this disease can cause Neuropathy. In this chapter, we provide an overview of CIPN, including: clinical predictors, frequency, and its impact on quality of life. Further, we highlight the pathophysiology and review the literature to date for agents designed to prevent or treat CIPN. We also highlight the most important ongoing clinical and translational research questions that hope to help better predict and prevent this toxicity. This includes optimizing the methods of assessment, using host specific factors (Race and genetics) to predict those more likely to experience CIPN, and determining how CIPN might impact clinical decisions toward therapy.

  • Pilot study of Scrambler therapy for the treatment of Chemotherapy-Induced Peripheral Neuropathy.
    Journal of Clinical Oncology, 2012
    Co-Authors: Deirdre R. Pachman, Breanna M. Linquist, Debra L. Barton, Kelliann C. Fee-schroeder, Thomas J. Smith, Daniel H. Lachance, Heshan Liu, Drew K. Seisler, Charles L. Loprinzi
    Abstract:

    9075 Background: Chemotherapy-Induced Peripheral Neuropathy (CIPN), a common dose-limiting side effect of chemotherapy, remains without known effective interventions. Preliminary data support that ...

Deirdre R. Pachman - One of the best experts on this subject based on the ideXlab platform.

  • Pilot evaluation of Scrambler therapy for the treatment of Chemotherapy-Induced Peripheral Neuropathy
    Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer, 2014
    Co-Authors: Deirdre R. Pachman, Debra L. Barton, Kelliann C. Fee-schroeder, Thomas J. Smith, Daniel H. Lachance, Heshan Liu, Drew K. Seisler, Breanna L. Weisbrod, Randy A. Shelerud, Andrea L. Cheville
    Abstract:

    Purpose Chemotherapy-Induced Peripheral Neuropathy (CIPN), a common side effect of chemotherapy, needs better effective treatments. Preliminary data support the use of Scrambler therapy, a device which treats pain via noninvasive cutaneous electrostimulation, for the treatment of CIPN. The current manuscript reports data from a pilot trial, performed to investigate the effect of Scrambler therapy for the treatment of established CIPN.

  • Management options for established Chemotherapy-Induced Peripheral Neuropathy.
    Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer, 2014
    Co-Authors: Deirdre R. Pachman, Maryam B. Lustberg, James C. Watson, Nina D. Wagner-johnston, Alexandre Chan, Larry Broadfield, Yin Ting Cheung, Christopher Steer, Dawn J Storey, Kavita D. Chandwani
    Abstract:

    Chemotherapy-Induced Peripheral Neuropathy (CIPN) is a common and debilitating condition associated with a variety of chemotherapeutic agents. Clinicians are cognizant of the negative impact of CIPN on cancer treatment outcomes and patients' psychosocial functioning and quality of life. In an attempt to alleviate this problem, clinicians and patients try various therapeutic interventions, despite limited evidence to support efficacy of these treatments. The rationale for such use is mostly based on the evidence for the treatment options in non-CIPN Peripheral Neuropathy syndromes, as this area is more robustly studied than is CIPN treatment. In this manuscript, we examine the existing evidence for both CIPN and non-CIPN treatments and develop a summary of the best available evidence with the aim of developing a practical approach to the treatment of CIPN, based on available literature and clinical practice experience.

  • The search for treatments to reduce Chemotherapy-Induced Peripheral Neuropathy.
    The Journal of clinical investigation, 2013
    Co-Authors: Deirdre R. Pachman, Charles L. Loprinzi, Axel Grothey
    Abstract:

    Oxaliplatin, a commonly used chemotherapeutic agent, is associated with both acute and chronic neurotoxicity. Chronic sensory Neuropathy can be dose limiting and may have detrimental effects on patients' quality of life. Preclinical studies provide an understanding of the pathophysiology of Chemotherapy-Induced Peripheral Neuropathy (CIPN) and may be important for developing effective preventative interventions. In this issue of the JCI, Coriat and colleagues used an animal model and a human pilot trial to evaluate the use of mangafodipir to reduce CIPN. Although many pilot clinical studies have reported promising data, larger clinical trials have repeatedly been unable to confirm these preliminary results. Thus, no agents are currently clinically recommended for the prevention of CIPN.

  • Pilot study of Scrambler therapy for the treatment of Chemotherapy-Induced Peripheral Neuropathy.
    Journal of Clinical Oncology, 2012
    Co-Authors: Deirdre R. Pachman, Breanna M. Linquist, Debra L. Barton, Kelliann C. Fee-schroeder, Thomas J. Smith, Daniel H. Lachance, Heshan Liu, Drew K. Seisler, Charles L. Loprinzi
    Abstract:

    9075 Background: Chemotherapy-Induced Peripheral Neuropathy (CIPN), a common dose-limiting side effect of chemotherapy, remains without known effective interventions. Preliminary data support that ...

  • Chemotherapy-Induced Peripheral Neuropathy: prevention and treatment.
    Clinical pharmacology and therapeutics, 2011
    Co-Authors: Deirdre R. Pachman, Debra L. Barton, James C. Watson, Charles L. Loprinzi
    Abstract:

    Chemotherapy-Induced Peripheral Neuropathy (CIPN) is a common, dose-limiting side effect of many chemotherapeutic agents. Although many therapies have been investigated for the prevention and/or treatment of CIPN, there is no well-accepted proven therapy. In addition, there is no universally accepted, well-validated measure for the assessment of CIPN. The agents for which there are the strongest preliminary data regarding their potential efficacy in preventing CIPN are intravenous calcium and magnesium (Ca/Mg) infusions and glutathione. Agents with the strongest supporting evidence for efficacy in the treatment of CIPN include topical pain relievers, such as baclofen/amitriptyline/ketamine gel, and serotonin and norepinephrine reuptake inhibitors, such as venlafaxine and duloxetine. Other promising therapies are also reviewed in this paper. Cutaneous electrostimulation is a nonpharmacological therapy that appears, from an early pilot trial, to be potentially effective in the treatment of CIPN. Finally, there is a lack of evidence of effective treatments for the paclitaxel acute pain syndrome (P-APS), which appears to be caused by neurologic injury.

Maree Colosimo - One of the best experts on this subject based on the ideXlab platform.

  • B Vitamin Complex and Chemotherapy-Induced Peripheral Neuropathy
    Current Oncology Reports, 2017
    Co-Authors: Janet Schloss, Maree Colosimo
    Abstract:

    Purpose of Review The purpose of this mini review is to evaluate the literature on B vitamins and Chemotherapy-Induced Peripheral Neuropathy.

  • b vitamin complex and chemotherapy induced Peripheral Neuropathy
    Current Oncology Reports, 2017
    Co-Authors: Janet Schloss, Maree Colosimo
    Abstract:

    The purpose of this mini review is to evaluate the literature on B vitamins and Chemotherapy-Induced Peripheral Neuropathy. One hundred and five journal articles were evaluated and nine manuscripts were included. There was one in vitro, one was an animal and seven were human studies. The in vitro study was a safety study on vitamin B6 and oxaliplatin which was not directly related to CIPN. The animal study evaluated vitamin B3 on paclitaxel administration with positive results. The human studies varied using a vitamin B complex, vitamin B12 only and vitamin B6. Chemotherapy-Induced Peripheral Neuropathy (CIPN) continues to plague patients and the medical fraternity. Currently, there are still no conclusive protective or treatment options. B vitamins have been found to play a role in CIPN prevention, but further studies are required to ascertain possible protection and treatment options.

  • B Vitamin Complex and Chemotherapy-Induced Peripheral Neuropathy
    Current Oncology Reports, 2017
    Co-Authors: Janet Schloss, Maree Colosimo
    Abstract:

    Purpose of Review The purpose of this mini review is to evaluate the literature on B vitamins and Chemotherapy-Induced Peripheral Neuropathy. Recent Findings One hundred and five journal articles were evaluated and nine manuscripts were included. There was one in vitro, one was an animal and seven were human studies. The in vitro study was a safety study on vitamin B_6 and oxaliplatin which was not directly related to CIPN. The animal study evaluated vitamin B_3 on paclitaxel administration with positive results. The human studies varied using a vitamin B complex, vitamin B_12 only and vitamin B_6. Summary Chemotherapy-Induced Peripheral Neuropathy (CIPN) continues to plague patients and the medical fraternity. Currently, there are still no conclusive protective or treatment options. B vitamins have been found to play a role in CIPN prevention, but further studies are required to ascertain possible protection and treatment options.

  • Chemotherapy-Induced Peripheral Neuropathy management.
    Journal of Clinical Oncology, 2016
    Co-Authors: Janet Schloss, Maree Colosimo, Luis Vitetta
    Abstract:

    154 Background: Neurological complications such as Chemotherapy-Induced Peripheral Neuropathy (CIPN) and neuropathic pain are frequent side-effects of neurotoxic chemotherapy agents. An increasing survival rate and frequent administration of adjuvant chemotherapy treatments involving neurotoxic agents makes it imperative that accurate diagnosis, prevention and treatment of these neurological complications be implemented to minimize the burden experienced by patients undergoing these treatments. Methods: To determine the potential use of pharmaceuticals, nutraceuticals and herbal medicines as adjuvants in cancer treatments a critical literature review was conducted by electronic and manual search on nine databases. These include PubMed, the Cochrane Library, Science Direct, Scopus, EMBASE, MEDLINE, Google Scholar and two Chinese databases CNKI and CINAHL. Thirty studies were selected for pharmaceutical agents, twenty-four studies for nutraceuticals and thirty-four studies for herbal medical trials. Seven a...

Janet Schloss - One of the best experts on this subject based on the ideXlab platform.

  • B Vitamin Complex and Chemotherapy-Induced Peripheral Neuropathy
    Current Oncology Reports, 2017
    Co-Authors: Janet Schloss, Maree Colosimo
    Abstract:

    Purpose of Review The purpose of this mini review is to evaluate the literature on B vitamins and Chemotherapy-Induced Peripheral Neuropathy.

  • b vitamin complex and chemotherapy induced Peripheral Neuropathy
    Current Oncology Reports, 2017
    Co-Authors: Janet Schloss, Maree Colosimo
    Abstract:

    The purpose of this mini review is to evaluate the literature on B vitamins and Chemotherapy-Induced Peripheral Neuropathy. One hundred and five journal articles were evaluated and nine manuscripts were included. There was one in vitro, one was an animal and seven were human studies. The in vitro study was a safety study on vitamin B6 and oxaliplatin which was not directly related to CIPN. The animal study evaluated vitamin B3 on paclitaxel administration with positive results. The human studies varied using a vitamin B complex, vitamin B12 only and vitamin B6. Chemotherapy-Induced Peripheral Neuropathy (CIPN) continues to plague patients and the medical fraternity. Currently, there are still no conclusive protective or treatment options. B vitamins have been found to play a role in CIPN prevention, but further studies are required to ascertain possible protection and treatment options.

  • B Vitamin Complex and Chemotherapy-Induced Peripheral Neuropathy
    Current Oncology Reports, 2017
    Co-Authors: Janet Schloss, Maree Colosimo
    Abstract:

    Purpose of Review The purpose of this mini review is to evaluate the literature on B vitamins and Chemotherapy-Induced Peripheral Neuropathy. Recent Findings One hundred and five journal articles were evaluated and nine manuscripts were included. There was one in vitro, one was an animal and seven were human studies. The in vitro study was a safety study on vitamin B_6 and oxaliplatin which was not directly related to CIPN. The animal study evaluated vitamin B_3 on paclitaxel administration with positive results. The human studies varied using a vitamin B complex, vitamin B_12 only and vitamin B_6. Summary Chemotherapy-Induced Peripheral Neuropathy (CIPN) continues to plague patients and the medical fraternity. Currently, there are still no conclusive protective or treatment options. B vitamins have been found to play a role in CIPN prevention, but further studies are required to ascertain possible protection and treatment options.

  • Chemotherapy-Induced Peripheral Neuropathy management.
    Journal of Clinical Oncology, 2016
    Co-Authors: Janet Schloss, Maree Colosimo, Luis Vitetta
    Abstract:

    154 Background: Neurological complications such as Chemotherapy-Induced Peripheral Neuropathy (CIPN) and neuropathic pain are frequent side-effects of neurotoxic chemotherapy agents. An increasing survival rate and frequent administration of adjuvant chemotherapy treatments involving neurotoxic agents makes it imperative that accurate diagnosis, prevention and treatment of these neurological complications be implemented to minimize the burden experienced by patients undergoing these treatments. Methods: To determine the potential use of pharmaceuticals, nutraceuticals and herbal medicines as adjuvants in cancer treatments a critical literature review was conducted by electronic and manual search on nine databases. These include PubMed, the Cochrane Library, Science Direct, Scopus, EMBASE, MEDLINE, Google Scholar and two Chinese databases CNKI and CINAHL. Thirty studies were selected for pharmaceutical agents, twenty-four studies for nutraceuticals and thirty-four studies for herbal medical trials. Seven a...

Debra L. Barton - One of the best experts on this subject based on the ideXlab platform.

  • Pilot evaluation of Scrambler therapy for the treatment of Chemotherapy-Induced Peripheral Neuropathy
    Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer, 2014
    Co-Authors: Deirdre R. Pachman, Debra L. Barton, Kelliann C. Fee-schroeder, Thomas J. Smith, Daniel H. Lachance, Heshan Liu, Drew K. Seisler, Breanna L. Weisbrod, Randy A. Shelerud, Andrea L. Cheville
    Abstract:

    Purpose Chemotherapy-Induced Peripheral Neuropathy (CIPN), a common side effect of chemotherapy, needs better effective treatments. Preliminary data support the use of Scrambler therapy, a device which treats pain via noninvasive cutaneous electrostimulation, for the treatment of CIPN. The current manuscript reports data from a pilot trial, performed to investigate the effect of Scrambler therapy for the treatment of established CIPN.

  • Pilot study of Scrambler therapy for the treatment of Chemotherapy-Induced Peripheral Neuropathy.
    Journal of Clinical Oncology, 2012
    Co-Authors: Deirdre R. Pachman, Breanna M. Linquist, Debra L. Barton, Kelliann C. Fee-schroeder, Thomas J. Smith, Daniel H. Lachance, Heshan Liu, Drew K. Seisler, Charles L. Loprinzi
    Abstract:

    9075 Background: Chemotherapy-Induced Peripheral Neuropathy (CIPN), a common dose-limiting side effect of chemotherapy, remains without known effective interventions. Preliminary data support that ...

  • Chemotherapy-Induced Peripheral Neuropathy: prevention and treatment.
    Clinical pharmacology and therapeutics, 2011
    Co-Authors: Deirdre R. Pachman, Debra L. Barton, James C. Watson, Charles L. Loprinzi
    Abstract:

    Chemotherapy-Induced Peripheral Neuropathy (CIPN) is a common, dose-limiting side effect of many chemotherapeutic agents. Although many therapies have been investigated for the prevention and/or treatment of CIPN, there is no well-accepted proven therapy. In addition, there is no universally accepted, well-validated measure for the assessment of CIPN. The agents for which there are the strongest preliminary data regarding their potential efficacy in preventing CIPN are intravenous calcium and magnesium (Ca/Mg) infusions and glutathione. Agents with the strongest supporting evidence for efficacy in the treatment of CIPN include topical pain relievers, such as baclofen/amitriptyline/ketamine gel, and serotonin and norepinephrine reuptake inhibitors, such as venlafaxine and duloxetine. Other promising therapies are also reviewed in this paper. Cutaneous electrostimulation is a nonpharmacological therapy that appears, from an early pilot trial, to be potentially effective in the treatment of CIPN. Finally, there is a lack of evidence of effective treatments for the paclitaxel acute pain syndrome (P-APS), which appears to be caused by neurologic injury.